课题基金 / 基金详情

UROKINASE--A LINK BETWEEN CELL ADHESION AND PROTEOLYSIS

UROKINASE--A LINK BETWEEN CELL ADHESION AND PROTEOLYSIS
尿激酶——细胞粘附和蛋白质水解之间的联系
批准号:
2734932
负责人:
DAVID A WALTZ
金额:
$8.37万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1994
资助国家:
美国
项目状态:
已结题
起止时间:
1994-07-01 至 1999-06-30

项目摘要

项目成果

DAVID A WALTZ的其他基金

相似基金

相关文献

中文摘要
翻译
该研究提案是一个多方面的项目和细胞迁移。 细胞相关蛋白水解中的中心元件对细胞的重要性 迁移和组织重塑是尿激酶(uPA)及其细胞表面 受体的 我们以前已经证明, 单核细胞依赖于uPA受体占有率, uPA抑制剂纤溶酶原激活物抑制剂1(派-1) 通过uPA/派复合物周转。 我们最近描述了一部小说 玻连蛋白受体,其活性与uPA受体占有率偶联。 由于玻连蛋白的已知功能是结合派-1,我们假设, uPA诱导的玻连蛋白结合启动细胞附着, 增强uPA/派-1复合物的形成调节uPA依赖性 蛋白水解并引发随后的细胞脱离。 为了验证这一 假设我们将表征玻连蛋白受体,并确定 uPA诱导的玻连蛋白与细胞周结合的重要性 蛋白水解和细胞迁移。
英文摘要
The research proposal is a multifaceted project and cellular migration. Central elements in cell-associated proteolysis important to cell migration and tissue remodeling are urokinase (uPA) and its cell-surface receptor. We have previously demonstrated that the adhesiveness of monocytic cells is dependent upon uPA receptor occupancy and regulated by the uPA inhibitor plasminogen activator inhibitor type 1 (PAI-1) through uPA/PAI complex turnover. We have recently described a novel vitronectin receptor whose activity is coupled to uPA receptor occupancy. As a known function of vitronectin is to bind PAI-1, we hypothesize that uPA-induced vitronectin binding initiates cellular attachment and by potentiating uPA/PAI-1 complex formation regulates uPA-dependent proteolysis and initiates subsequent cell detachment. To test this hypothesis we will characterize the vitronectin receptor and determine the importance of uPA-induced vitronectin binding on pericellular proteolysis and cellular migration.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, 28-DAY STUDY OF DEN
  • 批准号:
    7380767
  • 项目类别:
  • 资助金额:
    $0.81万
  • 财政年份:
    2006
  • 负责人:
    DAVID A WALTZ
  • 依托单位:
A PHASE 2 RANDOMIZED DOUBLE BLIND PARALLEL DOSE RANGING STUDY OF ORAL THERACLEC-
  • 批准号:
    7204732
  • 项目类别:
  • 资助金额:
    $4.58万
  • 财政年份:
    2005
  • 负责人:
    DAVID A WALTZ
  • 依托单位:
A MULTI-CENTER, DBL-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, 28-DAY STUDY OF INS37
  • 批准号:
    7204690
  • 项目类别:
  • 资助金额:
    $0.07万
  • 财政年份:
    2005
  • 负责人:
    DAVID A WALTZ
  • 依托单位:
DURATION OF ANTIMICROBIAL TREATMENT EFFECT FOLLOWING ADMINISTRATION OF TOBI SOLU
  • 批准号:
    7204675
  • 项目类别:
  • 资助金额:
    $0.36万
  • 财政年份:
    2005
  • 负责人:
    DAVID A WALTZ
  • 依托单位:
海外基金